Genomics · actively managed · ETF deep dive
ARK Genomic Revolution ETF ARKG
Cathie Wood's concentrated, discretionary bet on the genomics revolution — CRISPR, sequencing, AI-driven drug discovery — where the top 10 names are ~60% of the fund. High conviction, high fee, high volatility, and it lives or dies on ARK's stock-picking.
Price & momentum chart & stats through 2026-07-10
Data summary: last close $41.32 on 2026-07-10, 5% below the 52-week high of $43.57, 79% above the 52-week low of $23.09; trading above its 200-day average of $30.71. Trailing returns: YTD +42%, 1-year +58%, 3-year +27%, 5-year -55%.
What it holds
Top 10 holdings
| Holding | Ticker | Weight |
|---|---|---|
| Tempus AI | TEM | 8.0% |
| 10x Genomics | TXG | 7.7% |
| Twist Bioscience | TWST | 7.4% |
| CRISPR Therapeutics | CRSP | 6.7% |
| Absci | ABSI | 6.6% |
| Personalis | PSNL | 6.4% |
| Beam Therapeutics | BEAM | 4.5% |
| Guardant Health | GH | 4.3% |
| Eli Lilly | LLY | 4.3% |
| Illumina | ILMN | 4.0% |
Top-10 ≈ 60% of the fund (33 holdings total). Positions as of 2026-07-10, from the public aggregator (stockanalysis.com) (source). Holdings drift daily; weights are a snapshot, not live.
Sector mix live, FMP
- Healthcare97.0%
- Technology1.9%
- Financial Services0.9%
- Cash & Others0.1%
What this fund is
ARKG is actively managed — there is no index. ARK Investment Management (Cathie Wood) picks ~30–40 high-conviction companies it believes will benefit from the genomics revolution: CRISPR gene editing, DNA sequencing, molecular diagnostics, and AI-driven drug discovery.
It is highly concentrated: around 33 holdings, with the top 10 near 60% of the fund and individual positions running 4–8%. Those are far larger single-name bets than any passive fund here. Sector is ~98% health care, skewed to unprofitable small/mid-cap disruptors.
It is a fully transparent active ETF — ARK publishes holdings and even daily trades. Return dispersion is driven by a handful of large positions and by the manager's discretion, not by a rule.
The Synthos read
How the tracked themes this fund rides are reading right now — conviction-weighted net stance from independent expert voices in the Synthos knowledge base (management/officials laned out). Snapshot as of 2026-07-12.
| Tracked theme | Net stance (−100 to +100) | Recent drift | Reliability |
|---|---|---|---|
| GLP-1 / obesity / biotech Closest tracked theme (biotech), but ARKG is genomics/tools-heavy and unprofitable-growth-tilted, not GLP-1 — read broad biotech-cycle sentiment, not name-level signal. | up +100 Very Bullish | — 8 claims | Insufficient |
Reliability tiers: Full ≥ 25 claims in the current window, Provisional 10–24, Insufficient < 10 (read as directional only). Net stance is a rate-of-change signal about the theme, not a price target for this fund and not advice. Themes can be right while the fund’s structure works against you.
Cost & structure
Expense ratio 0.75% (issuer, cross-checks against FMP).
1940-Act open-end, actively managed ETF (ARK ETF Trust), inception 2014. No scheduled rebalance — the manager adjusts continuously, historically with high turnover.
Fully transparent (daily holdings + trade notifications). Note: ARK's issuer page blocked automated verification at build time; the 0.75% fee and holdings were confirmed via public aggregators as of the dates shown.
Honest fit
The job it does
- Concentrated, high-conviction access to the genomics/gene-editing frontier in one line.
- Exposure to unprofitable early-stage disruptors most broad-biotech funds underweight.
- A fully transparent active vehicle — you can see exactly what ARK owns and trades.
What it does not do
- Is not diversified — top-10 ~60%, so a few positions drive everything; far more volatile than XBI.
- Is not a broad biotech/pharma proxy — it skews to unprofitable small/mid-cap genomics, not large-cap drugs.
- Is not passive or cheap — 0.75% fee plus manager risk; performance hinges on ARK's stock-picking.
What would change this read (falsifiers)
- A rate up-cycle punishes long-duration, cash-burning growth — ARKG's exact profile — most severely.
- Manager / process risk: ARK's discretionary calls can be wrong for years; the fund has a history of extreme drawdowns.
- If you want the genomics theme without single-manager and concentration risk, a broad biotech fund is the lower-variance route.